Seniors’ Access to Critical Medications Act of 2025
- Sponsor
- Rep. Harshbarger, Diana [R-TN-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 29, 2025
Bottom line
The bill establishes a temporary exception to the Stark Law, enabling physician practices to dispense specific Medicare Part D drugs directly to patients, while also mandating a study and reducing a Medicare fund.
What it actually does
This bill amends the Social Security Act to create a temporary exception to the physician self-referral prohibition (Stark Law) for certain outpatient prescription drugs covered under Medicare Part D. This exception, effective from January 1, 2026, to December 31, 2030, allows physician practices to dispense these drugs if specific conditions regarding patient relationship and prior in-person encounters are met. The bill also mandates a GAO study on physician dispensing practices and reduces the Medicare Improvement Fund by $18 million.
Proponents argue
Proponents argue that this bill enhances patient access to critical medications by allowing them to obtain prescriptions directly from their prescribing physician's office, which can improve convenience, medication adherence, and continuity of care, particularly for elderly Medicare beneficiaries. They suggest it streamlines the healthcare process and reduces the burden of separate pharmacy visits.
Opponents contend
Opponents would likely contend that creating an exception to the physician self-referral prohibition reintroduces potential conflicts of interest, where physicians might have a financial incentive to prescribe and dispense drugs from their own practice. This could lead to over-prescription, higher costs for Medicare and beneficiaries, and unfair competition for independent pharmacies, potentially undermining the integrity of the healthcare system.
The bill is concise and can be read and understood quickly by an informed reader.
Section 2(a), amending Section 1877(b) of the Social Security Act
Temporary Exception to Physician Self-Referral Prohibition for Part D Drugs
This provision establishes a new, temporary exception to the 'Stark Law,' which generally prohibits physicians from referring Medicare patients for designated health services to entities with which the physician or their family member has a financial relationship. Specifically, from January 1, 2026, to December 31, 2030, physician practices can dispense certain Medicare Part D outpatient prescription drugs if the patient has an ongoing relationship with the prescribing physician, had a recent in-person encounter, and the drugs are dispensed from the practice's building, including via mail or delivery.
Supporters argue
Supporters argue this provision enhances patient convenience and adherence by allowing patients to pick up critical medications directly from their doctor's office, especially for those with mobility issues or complex conditions. They contend it fosters continuity of care and reduces the burden of multiple stops, improving the overall patient experience.
Critics contend
Critics contend that this exception reintroduces financial incentives for physicians to self-refer, potentially leading to over-prescription of drugs or steering patients away from more cost-effective pharmacy options. They argue it could harm independent pharmacies by reducing their prescription volume and potentially increase overall Medicare costs due to a lack of competitive pricing.
Tradeoffs
The provision balances the desire for enhanced patient convenience and integrated care against concerns about potential conflicts of interest, market distortion in the pharmacy sector, and the risk of increased healthcare costs.
Section 2(b)
GAO Study on Physician-Owned Pharmacies and Dispensing Practices
This section mandates the Comptroller General of the United States (GAO) to conduct a comprehensive study. The study will examine pharmacies and pharmacy networks that show a significant increase in Medicare Part D drug dispensing after the bill's enactment. It will analyze characteristics of these entities, their ownership by physician practices, and common arrangements for integrating drug dispensing into physician practices, including potential influences on prescribing patterns and measures taken to mitigate conflicts of interest. A report on the findings is due to Congress within three years.
Section 3
Reduction in Medicare Improvement Fund
This section amends Section 1898(b)(1) of the Social Security Act by reducing the amount in the Medicare Improvement Fund. The fund's allocation is decreased from $1,804,000,000 to $1,786,000,000, representing a reduction of $18,000,000. This fund is typically used for future improvements and administrative needs within the Medicare program.
The bill reduces the Medicare Improvement Fund by $18,000,000, changing its allocation from $1,804,000,000 to $1,786,000,000.
Section 3
Why it matters:This is a typical legislative practice for budget offsets, often placed in a separate section at the end of a bill. While not necessarily evasive, it is a significant fiscal detail that is not highlighted as a main policy point.
Case for: Supporters would argue that this reduction serves as a necessary budget offset to help ensure the fiscal neutrality or responsibility of the bill's primary policy changes, or as a contribution to broader deficit reduction efforts.
Case against: Critics might argue that reducing funds specifically designated for Medicare improvements could have long-term negative consequences for beneficiaries by limiting resources for future program enhancements, innovations, or addressing unforeseen challenges within the Medicare system.
Estimated impact: Reduces the Medicare Improvement Fund by $18 million.